Zentalis Pharmaceuticals, Inc. Operating Expenses
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Operating Expenses of $44.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-06-30 was $44.39M, a 23.11% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-03-31 was $37.85M, a 17.03% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-12-31 was $37.39M, a 51.26% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-09-30 was $33.73M, a 34.41% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. operating expenses for fiscal 2025 was $152.81M, a 40.91% decline from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. operating expenses for fiscal 2024 was $258.62M, a 13.65% decline from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. operating expenses for fiscal 2023 was $299.51M, a 31.78% increase from fiscal 2022.
- Zentalis Pharmaceuticals, Inc. operating expenses for fiscal 2022 was $227.29M, a 4.96% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $44.39M 10-Q · filed 2026-08-06 | $82.25M 10-Q · filed 2026-08-06 | $119.64M derived: sum of 3 quarters · filed 2026-08-06 | $153.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $37.85M 10-Q · filed 2026-05-12 | $75.25M derived: sum of 2 quarters · filed 2026-05-12 | $108.98M derived: sum of 3 quarters · filed 2026-05-12 | $145.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $37.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $71.13M derived: sum of 2 quarters · filed 2026-03-26 | $107.19M derived: sum of 3 quarters · filed 2026-08-06 | $152.81M 10-K · filed 2026-03-26 |
| 2025-09-30 | $33.73M 10-Q · filed 2025-11-10 | $69.79M derived: sum of 2 quarters · filed 2026-08-06 | $115.42M 10-Q · filed 2025-11-10 | $192.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $36.06M 10-Q · filed 2026-08-06 | $81.68M 10-Q · filed 2026-08-06 | $158.40M derived: sum of 3 quarters · filed 2026-08-06 | $209.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $45.62M 10-Q · filed 2026-05-12 | $122.34M derived: sum of 2 quarters · filed 2026-05-12 | $173.77M derived: sum of 3 quarters · filed 2026-05-12 | $238.92M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $76.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $128.15M derived: sum of 2 quarters · filed 2026-03-26 | $193.29M derived: sum of 3 quarters · filed 2026-03-26 | $258.62M 10-K · filed 2026-03-26 |
| 2024-09-30 | $51.43M 10-Q · filed 2025-11-10 | $116.58M derived: sum of 2 quarters · filed 2025-11-10 | $181.91M 10-Q · filed 2025-11-10 | $249.83M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | $65.15M 10-Q · filed 2025-08-06 | $130.47M 10-Q · filed 2025-08-06 | $198.40M derived: sum of 3 quarters · filed 2026-03-26 | $261.11M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | $65.33M 10-Q · filed 2025-05-14 | $133.25M derived: sum of 2 quarters · filed 2026-03-26 | $195.97M derived: sum of 3 quarters · filed 2026-03-26 | $299.88M derived: sum of 4 quarters · filed 2026-03-26 |
| 2023-12-31 | $67.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $130.64M derived: sum of 2 quarters · filed 2026-03-26 | $234.56M derived: sum of 3 quarters · filed 2026-03-26 | $299.51M 10-K · filed 2026-03-26 |
| 2023-09-30 | $62.72M 10-Q · filed 2024-11-12 | $166.63M derived: sum of 2 quarters · filed 2024-11-12 | $231.59M 10-Q · filed 2024-11-12 | $283.34M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | $103.92M 10-Q · filed 2024-08-09 | $168.87M 10-Q · filed 2024-08-09 | $220.62M derived: sum of 3 quarters · filed 2025-03-26 | $274.82M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | $64.95M 10-Q · filed 2024-05-07 | $116.71M derived: sum of 2 quarters · filed 2025-03-26 | $170.90M derived: sum of 3 quarters · filed 2025-03-26 | $234.36M derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-12-31 | $51.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $105.95M derived: sum of 2 quarters · filed 2025-03-26 | $169.41M derived: sum of 3 quarters · filed 2025-03-26 | $227.29M 10-K · filed 2025-03-26 |
| 2022-09-30 | $54.19M 10-Q · filed 2023-11-06 | $117.65M derived: sum of 2 quarters · filed 2023-11-06 | $175.53M 10-Q · filed 2023-11-06 | $223.73M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $63.46M 10-Q · filed 2023-08-09 | $121.34M 10-Q · filed 2023-08-09 | $169.53M derived: sum of 3 quarters · filed 2023-08-09 | $232.40M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $57.88M 10-Q · filed 2023-05-10 | $106.07M derived: sum of 2 quarters · filed 2023-05-10 | $168.94M derived: sum of 3 quarters · filed 2023-05-10 | $224.07M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $48.19M 10-K · filed 2022-02-24 | $111.06M derived: sum of 2 quarters · filed 2022-11-09 | $166.19M derived: sum of 3 quarters · filed 2022-11-09 | $216.54M 10-K · filed 2024-02-27 |
| 2021-09-30 | $62.87M 10-Q · filed 2022-11-09 | $118.00M derived: sum of 2 quarters · filed 2022-11-09 | $168.35M 10-Q · filed 2022-11-09 | $208.59M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $55.13M 10-Q · filed 2022-08-09 | $105.48M 10-Q · filed 2022-08-09 | $145.72M derived: sum of 3 quarters · filed 2022-08-09 | $180.49M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $50.35M 10-Q · filed 2022-05-05 | $90.59M derived: sum of 2 quarters · filed 2022-05-05 | $125.36M derived: sum of 3 quarters · filed 2022-05-05 | $152.74M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $40.24M 10-K · filed 2022-02-24 | $75.01M derived: sum of 2 quarters · filed 2022-02-24 | $102.39M derived: sum of 3 quarters · filed 2022-02-24 | $118.79M 10-K · filed 2023-03-01 |
| 2020-09-30 | $34.77M 10-K · filed 2022-02-24 | $62.14M derived: sum of 2 quarters · filed 2022-02-24 | $78.54M 10-Q · filed 2021-11-10 | $93.45M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $27.38M 10-K · filed 2022-02-24 | $43.77M 10-Q · filed 2021-08-12 | $58.68M derived: sum of 3 quarters · filed 2022-02-24 | $71.26M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $16.40M 10-K · filed 2022-02-24 | $31.30M derived: sum of 2 quarters · filed 2022-02-24 | $43.89M derived: sum of 3 quarters · filed 2022-02-24 | $54.52M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $14.90M 10-K · filed 2021-03-25 | $27.49M derived: sum of 2 quarters · filed 2021-03-25 | $38.12M derived: sum of 3 quarters · filed 2021-03-25 | $46.84M 10-K · filed 2022-02-24 |
| 2019-09-30 | $12.58M 10-K · filed 2021-03-25 | $23.22M derived: sum of 2 quarters · filed 2021-03-25 | $31.94M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $10.63M 10-K · filed 2021-03-25 | $19.36M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $8.72M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |